ATE331507T1 - Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung - Google Patents

Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung

Info

Publication number
ATE331507T1
ATE331507T1 AT04712898T AT04712898T ATE331507T1 AT E331507 T1 ATE331507 T1 AT E331507T1 AT 04712898 T AT04712898 T AT 04712898T AT 04712898 T AT04712898 T AT 04712898T AT E331507 T1 ATE331507 T1 AT E331507T1
Authority
AT
Austria
Prior art keywords
sphingolipid
present
safingol
pharmaceutical composition
composition containing
Prior art date
Application number
AT04712898T
Other languages
English (en)
Inventor
Barry James Maurer
Patrick C Reynolds
Rao B Vishnuvajjala
Shanker Gupta
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Application granted granted Critical
Publication of ATE331507T1 publication Critical patent/ATE331507T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04712898T 2003-02-21 2004-02-19 Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung ATE331507T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44953603P 2003-02-21 2003-02-21

Publications (1)

Publication Number Publication Date
ATE331507T1 true ATE331507T1 (de) 2006-07-15

Family

ID=32927531

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04712898T ATE331507T1 (de) 2003-02-21 2004-02-19 Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung

Country Status (9)

Country Link
US (1) US7476692B2 (de)
EP (1) EP1594488B1 (de)
JP (2) JP4842800B2 (de)
AT (1) ATE331507T1 (de)
CA (1) CA2516399C (de)
DE (1) DE602004001393T2 (de)
ES (1) ES2270347T3 (de)
MX (1) MXPA05008860A (de)
WO (1) WO2004075834A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ572601A (en) 2006-03-29 2012-03-30 Univ Wayne State Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
EP2669267B1 (de) * 2009-11-12 2018-01-10 Texas Tech University Zusammensetzungen und Verfahren zur Behandlung hyperproliferativer Erkrankungen
EP3024441A4 (de) * 2013-07-25 2017-04-19 Nemucore Medical Innovations, Inc. Nanoemulsionen aus einem hydrophoben platinderivat
IT201600105201A1 (it) * 2016-10-19 2018-04-19 Nutrilinea Srl Uso della fosfatidilserina per la prevenzione e il trattamento dei disturbi della prostata e relative composizioni farmaceutiche e nutraceutiche
US10034895B2 (en) * 2017-11-30 2018-07-31 Joel Steven Goldberg Local application of D-lactic acid dimer is selectively cytotoxic when applied to cancer cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0716589A4 (de) * 1993-07-23 1997-06-11 Morris Herstein Kosmetische, die hauterneuerung stimulierende zusammensetzung mit langzeit-irritationskontrolle
US5635536A (en) 1994-12-07 1997-06-03 Pharmacia & Upjohn Aktiebolag Emulsion suitable for administering a sphingolipid
EP0866693B1 (de) * 1995-10-18 2003-08-20 Mary Kay Inc. Topisch angewandte strukturelle behandlungen der zellulitis
EP1091745B1 (de) * 1998-06-29 2008-10-01 Children's Hospital Of Los Angeles Behandlung hyperproliferativer erkrankungen
US6368831B1 (en) 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
JP3220434B2 (ja) 1998-12-28 2001-10-22 花王株式会社 化粧料
KR100343885B1 (ko) * 1999-07-20 2002-07-19 주식회사 두산 파이토스핑고신의 수용액의 제조 방법
KR100371491B1 (ko) * 1999-07-27 2003-02-07 주식회사 두산 피부 보호용 크림조성물
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
JP3896234B2 (ja) * 1999-12-24 2007-03-22 花王株式会社 化粧料
EP1287815A1 (de) * 2001-08-31 2003-03-05 Cosmoferm B.V. Verwendung einer Sphingoidbase zur Inhibierung von Ceramidase-Aktivität
JP4220698B2 (ja) * 2001-12-10 2009-02-04 花王株式会社 皮膚外用剤
JP4119646B2 (ja) * 2001-12-10 2008-07-16 花王株式会社 セラミド類乳化物の製造法
CN100340227C (zh) 2001-12-10 2007-10-03 花王株式会社 神经酰胺类乳化物
EP1545619B1 (de) * 2002-09-05 2008-01-23 Galderma S.A. Lösung zur nagel-verwendung

Also Published As

Publication number Publication date
DE602004001393D1 (de) 2006-08-10
WO2004075834A2 (en) 2004-09-10
WO2004075834A3 (en) 2005-03-24
JP4842800B2 (ja) 2011-12-21
JP2011126886A (ja) 2011-06-30
EP1594488A2 (de) 2005-11-16
DE602004001393T2 (de) 2007-06-14
JP2006518743A (ja) 2006-08-17
CA2516399A1 (en) 2004-09-10
EP1594488B1 (de) 2006-06-28
CA2516399C (en) 2013-05-14
MXPA05008860A (es) 2005-10-05
US20050187186A1 (en) 2005-08-25
US7476692B2 (en) 2009-01-13
ES2270347T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
DE60222573D1 (de) Mikroemulsionbildende herbizidkonzentrate, mikroemulsionen und verfahren
UA92470C2 (ru) Стабильный при хранении инфузионный раствор дигидроптеридинонов
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
RS50360B (sr) Farmaceutske formulacije derivata platine
NO20062877L (no) Stabile liposomsammensetninger som omfatter lipofile aminholdige farmasoytiske midler
DE60130023D1 (de) Behandlung der nebenwirkungen von statinen
ATE430564T1 (de) Stabile pharmazeutische zusammensetzungen aus antitumoralen platin-(ii)-mitteln
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
MY151470A (en) Controlled release solid preparation
ES2184310T3 (es) Formulacion autoemulsionante para compuestos lipofilos acidos.
IL168836A (en) Pyrimidine-sulfamides and their use as endothelin receptor antagonist
EA200800370A1 (ru) Новая фармацевтическая лекарственная форма ингибитора фермента циклооксигеназы с модифицированным высвобождением
ATE405292T1 (de) Injektierbare wässrige paclitaxel-lösungen und verfahren zu ihrer herstellung
RS52966B (en) FORM OF THE THERAPEUTIC APPLICATION OF ACTIVE PEPTIDES WITH THE LONG TERM RELEASE OF THE ACTIVE INGREDIENT
RU2009102803A (ru) Пригодный для инъекции состав антибиотика и раствор для его внутреннего введения
WO2003086324A3 (en) Preparation and use of a stable formulation of allosteric effector compounds
ATE331507T1 (de) Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung
ATE494894T1 (de) Viruzide wirkungen von einer zubereitung enthaltend cetylpyridiniumchlorid und zitronensäure
IL172358A0 (en) Colchicoside analogues
ATE298256T1 (de) Biomaterial in form von mikropartikeln von hyaluronsaure zur medizinischen verwendung
JPH075456B2 (ja) 点眼液
DE602004007149D1 (de) Stabile pharmazeutische zusammensetzung einer fluorether-verbindung für die anästhesie, verfahren zur stabilisierung einer fluorether-verbindung, verwendung eines stabilisierungsmittels zum ausschluss des abbaus einer fluorether-verbindung
JPH07324034A (ja) フマル酸ケトチフェン含有の点眼剤
EE05090B1 (et) Tsklipostiinihend kasutamiseks diabeedivastase ravimina, seda sisaldav farmatseutiline preparaat,hendi ja preparaadi valmistamine ning selleks vajalik mikroorganism

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties